Lactate in the Gut
NCT04299815 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2020-09-30
Summary
Lactate is formed naturally in the body in example during physical activity. However, lactate is also formed during food fermentation where certain bacterial strains form lactate. Lactate can also be produced chemically. An example of this is Ringer-lactate which is used for volume replacement when treating dehydrated patients.
As a source of carbon-molecules, lactate is believed to be an important oxidative fuel source in all major organs and yields adenosine triphosphate (ATP) production through Krebs cycle, the Electron Transport Chain in the mitochondria as well as by being a key precursor for gluconeogenesis.
Metformin is the first drug of choice for type 2 diabetes treatment. Use of metformin often results in a small but significant weight loss in overweight users. It is known that metformin increases the lactate concentration in the gut. It is also known also know that metformin use is associated with an increase in blood concentrations of growth differentiation factor 15 (GDF-15). Receptors for GDF-15 can be found in parts of the brain associated with control of appetite. In rats increases in \[GDF-15\] results in a decrease in appetite and thus weight loss. GDF-15 is thought to be involved in the normal energy homeostasis.
With this study the investigators want to examine the hormonal, metabolic and mechanical effects of lactate in the gut in healthy volunteers. Our hypothesis is that lactate has beneficial effects which may be though an increase in GDF-15 in the blood.
Volunteers will undergo two study days separated by at least 7 days and a maximum of 1 month.
* On day one volunteers will drink a sodium-lactate solution (intervention). The investigators will also administrate 1500mg paracetamol to assess gastric emptying and do blood samples over 4 hours. The investigators measure \[lactate\] every 15 min. Every hour the investigators will ask volunteers questions regarding hunger and thoughts of future food intake (questionnaire). After 4 hours of blood sampling the investigators will serve volunteers an all-you-can-eat meal of sandwich and measure how must they ate.
* On day two volunteers will drink a sodium chloride solution. Furthermore, the investigators administrate intravenous D/L sodium lactate in order to reach the same plasma \[lactate\] on day 2 as was done on day 1. The rest of day two is identical to day 1.
Conditions
- Lactate
- Healthy
- Hyperlactatemia
Interventions
- DRUG
-
Oral Sodium Lactate
25 grams of D/L lactate dissolved in 300mL water.
- DRUG
-
Intravenous sodium lactate
intravenous sodium lactate + oral sodium-chlorid solution
Sponsors & Collaborators
-
University of Aarhus
lead OTHER
Principal Investigators
-
Nikolaj Rittig, postdoc · Steno Diabetes Center Aarhus (SDCA), Aarhus universitetshospital
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-04-01
- Primary Completion
- 2020-07-29
- Completion
- 2020-07-29
Countries
- Denmark
Study Locations
More Related Trials
-
Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders
NCT00718627 ·Status: COMPLETED ·Phase: PHASE2
-
Quantitative Liver Function Tests Using Cholates
NCT01907074 ·Status: TERMINATED ·Phase: PHASE2
-
The Effect of 40gr Okara on Gastric Emptying
NCT01079585 ·Status: UNKNOWN ·Phase: NA
-
Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients
NCT05279586 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy
NCT06072521 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Weight-Adjusted Dosing of 3-OHB in Patients With Chronic Heart Failure
NCT04594265 ·Status: UNKNOWN ·Phase: PHASE2
-
Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders
NCT01195753 ·Status: TERMINATED ·Phase: PHASE2
-
Phase II Study of Lactulose and Circadian Rhythms in Patients With Cirrhosis
NCT00004796 ·Status: COMPLETED ·Phase: PHASE2
-
Expanded Access Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Liver Injury in Children
NCT02925520 ·Status: NO_LONGER_AVAILABLE
-
Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury
NCT02010034 ·Status: COMPLETED ·Phase: NA
-
A Study of Controlled Lactulose Withdrawal
NCT00914056 ·Status: COMPLETED ·Phase: NA
-
In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop
NCT06493799 ·Status: RECRUITING ·Phase: PHASE3
-
Dietary Supplementation With Butyrate in Individuals With Liver Steatosis and Metabolic Syndrome
NCT06398522 ·Status: COMPLETED ·Phase: NA
-
N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure
NCT00248625 ·Status: COMPLETED ·Phase: PHASE3
-
GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis
NCT01589523 ·Status: COMPLETED ·Phase: PHASE3
-
Serum Metabolics-based Method for Diagnosing Bile Acid Diarrhoea
NCT06548009 ·Status: COMPLETED
-
Synbiotics Interventions for Managing Cirrhosis and Its Complications
NCT05687409 ·Status: COMPLETED ·Phase: PHASE4
-
Osmotic Fragility in Red Blood Cells of Pediatric Patients With Cholestatic Liver Disease
NCT05582447 ·Status: ACTIVE_NOT_RECRUITING
-
Testing the Potential Metabolic Effect of the Human Gut Bacterial Peptide, RUCILP, in Healthy Men
NCT06923839 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Effect of Pancreatic Polypeptide on Gastric Motor Function and Food Intake in Humans
NCT03854708 ·Status: COMPLETED ·Phase: PHASE4
-
Randomized Study of the Use of Intravenous Choline Supplementation in Long Term Total Parenteral Nutrition
NCT00004697 ·Status: COMPLETED ·Phase: NA
-
S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE
NCT01446523 ·Status: COMPLETED ·Phase: NA
-
Liver Metabolic Functions in Patients With Citrin Deficiency and Healthy Subjects
NCT07055269 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Examination of the Metabolic Effects of Direct Bile Salt Delivery to the Ileum in Humans
NCT03201952 ·Status: TERMINATED ·Phase: PHASE1
-
Patient-Initiated and ConTrolled Oral Refeeding (PICTOR)
NCT01728896 ·Status: COMPLETED ·Phase: NA